STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #543 by analyst upside · 2026-09-09
QNCX
Quince Therapeutics, Inc.
Healthcare · Market Cap $30M · P/E 0x
ANALYST PRICE TARGET
+161.7%
implied upside to consensus target
Current Price $29.5
Consensus Target $77.2
Bull Target $98.0
Bear Target $68.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
1
Sell
0
52-Week Low $15.1
52-Week High $910.0
YTD Return -95.1%
FUNDAMENTALS
Market Cap $30M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-210.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.1
52-Week High $910.0
Current Price $29.5
Bear Target $68.0
Bull Target $98.0
● Now $29.5 ● Target $77.2
TRADING DATA
Avg Volume 30K
YTD Return -95.1%
Analyst Count 5
Consensus Buy
Upside to Target +161.7%
Last Updated 2026-09-09

ANALYST SUMMARY

Quince Therapeutics, Inc. (QNCX) is currently trading at $29.5 with a Wall Street consensus price target of $77.2, implying potential upside of 161.7% over the next 12 months. 5 analysts currently cover QNCX, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $98.0, while the most cautious has a target of $68.0.

QNCX operates in the Healthcare sector with a market capitalisation of $30M. The stock is down 95.1% year-to-date and is currently trading near the lower end of its 52-week range of $15.1 – $910.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for QNCX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald reit
Overweight → Overweight 2026-08-18 40% win rate (10 calls)
Oppenheimer ● Initiated
Outperform → Outperform 2026-07-29 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2026-06-24 29% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-06-23 40% win rate (10 calls)
Citizens ↓ Downgrade
Market Outperform → Market Perform 2026-01-30 Building track record
D. Boral Capital ↓ Downgrade
Buy → Hold 2026-01-30 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-01-29 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-12-15 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
14/30
Consensus clarity
10/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →